Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly …

Abstract Development of tau-based therapies for Alzheimer’s disease requires an understanding
of the timing of disease-related changes in tau. We quantified the phosphorylation state …

Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

Objective We examined whether plasma β-amyloid (Aβ)42/Aβ40, as measured by a high-precision
assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p-tau181/…

We developed stable isotope labeling and mass spectrometry approaches to measure the
kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) …

Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation,
hypometabolism, and structural decline that precedes the onset of clinical dementia. …

Neuroimaging data emphasize that older adults often show greater extent of brain activation
than younger adults for similar objective levels of difficulty. A possible interpretation of this …

Aggregated insoluble tau is one of two defining features of Alzheimer’s disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and clinical …

Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into plaques …

Environmental velocity has emerged as an important concept but remains theoretically
underdeveloped, particularly with respect to its multidimensionality. In response, we develop a …